Technologies

time icon Dec. 1, 2011

Predictive marker for taxane responsiveness of cancer patients

Technology description

Background

Taxanes are chemotherapeutic drugs that are extensively used for a range of cancers, such as breast, ovarian, prostrate, and lung cancer, among others.

Description

University of Alberta researchers have identified a predictive marker to screen patients that are being considered for taxane-based chemotherapy.

Elevated levels of this protein marker correlate with increased breast cancer patient survival after adjuvant-taxane treatment. In vitro experiments using siRNA to knock-down protein expression demonstrate that the marker is a critical effector molecule in the mechanism of action of taxane induced cytotoxicity.

Physicians will now be able to make more informed treatment decisions in regards to taxane usage based on an antibody-based assay to screen patient biopsy samples for the expression levels of the predictive marker. Further research is ongoing to validate this method utilizing samples from a large randomized controlled clinical trial.

Advantages

  • Enables physicians to identify cancer patients that are likely to benefit from taxane drug treatement.
  • Prevent taxane exposure and limit the serious side effects and high costs associated with taxane therapy in patients that would not likely respond to such treatment.
  • Compatible with standard clinical procedures already in place for E.R., P.R. and HER-2 evaluation.

由于技术保密工作限制,技术信息无法完全展现,请通过邮箱或短信联系我们,获取更多技术资料。

More information

Institution
Categories
  • Oncology
  • Diagnosis and treatment
Keywords:

critical effector molecule

taxane induced cytotoxicity

taxane usage based

method utilizing samples

informed treatment decisions

下载 PDF 文档


感兴趣

Contact us

知繁业茂-yintrust logo知繁业茂-Branchly Innovation logo 知繁业茂-autmasia logo迈科技 logo